Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study
Ariela Noy(Memorial Sloan Kettering Cancer Center), Robert W. Chen, Isaiah W. Dimery(The University of Texas MD Anderson Cancer Center), Shachar Peles(Medical College of Wisconsin), Catherine Thiéblemont(Université Paris Cité), Peter Martin(Northwestern University), Franck Morschhauser(Hôpital Claude Huriez), Brian Munneke(Pharmacyclics (United States)), Shuo Ma(Nantong University), Sven de Vos(University of California, Los Angeles), Morton Coleman(Cornell University), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Stephen D. Smith(Seattle Cancer Care Alliance), Darrin M. Beaupre(Pharmacyclics (United States)), Graham P. Collins(Churchill Hospital), Alina Smith(AbbVie (United States))
Cited by 10
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|1990|1.4k